Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Appendix 1: CONSORT Checklist
Response to antibiotics of women with symptoms of urinary tract infection
and negative dipstick urine test results: a randomised controlled trial
|
PAPER SECTION |
Item |
Description |
Reported on Page # |
|
TITLE & ABSTRACT |
1 |
How participants were allocated to interventions (e.g., "random allocation", "randomized", or "randomly assigned"). |
2 |
|
INTRODUCTION |
2 |
4,5 |
|
|
METHODS |
3 |
Eligibility criteria for participants and the settings and locations where the data were collected. |
5,6 |
|
Interventions |
4 |
6 |
|
|
Objectives |
5 |
2,5 |
|
|
Outcomes |
6 |
Clearly defined primary and secondary outcome measures and, when applicable, any methods used to enhance the quality of measurements . |
7 |
|
Sample size |
7 |
How sample size was determined and, when applicable, explanation of any interim analyses and stopping rules. |
8 |
|
Randomization -- |
8 |
Method used to generate the random allocation sequence, including details of any restrictions |
6 |
|
Randomization -- |
9 |
Method used to implement the random allocation sequence clarifying whether the sequence was concealed until interventions were assigned. |
6 |
|
Randomization -- |
10 |
5,6,7 |
|
|
Blinding (masking) |
11 |
Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment. When relevant, how the success of blinding was evaluated. |
7 |
|
Statistical methods |
12 |
Statistical methods used to compare groups for primary outcome(s); Methods for additional analyses, such as subgroup analyses and adjusted analyses. |
8 |
|
RESULTS Participant flow |
13 |
Flow of participants through each stage (see diagram). Specifically, for each group report the numbers of participants randomly assigned, receiving intended treatment, completing the study protocol, and analyzed for the primary outcome. Describe protocol deviations from study as planned, together with reasons. |
6,7,8,920 |
|
Recruitment |
14 |
9 |
|
|
Baseline data |
15 |
Baseline demographic and clinical characteristics of each group. |
19 |
|
Numbers analyzed |
16 |
9,20 |
|
|
Outcomes and estimation |
17 |
9,10 |
|
|
Ancillary analyses |
18 |
Address multiplicity by reporting any other analyses performed, |
N/A |
|
Adverse events |
19 |
All important adverse events or side effects in each intervention group. |
11 |
|
DISCUSSION |
20 |
Interpretation of the results, taking into account study hypotheses, sources of potential bias or imprecision and the dangers associated with multiplicity of analyses and outcomes. |
11,12 |
|
Generalizability |
21 |
12 |
|
|
Overall evidence |
22 |
General interpretation of the results in the context of current evidence. |
12,13 |